Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (214)

2024

  1. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets

    Rheumatology (United Kingdom), Vol. 63, Núm. SI, pp. SI96-SI106

  2. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus

    Expert Review of Clinical Immunology, Vol. 20, Núm. 4, pp. 359-373

  3. Clinical Predictors of Mood Disorders and Prevalence of Neuropsychiatric Symptoms in Patients with Systemic Lupus Erythematosus

    Journal of Clinical Medicine, Vol. 13, Núm. 18

  4. De-imFAR phase II project: a study protocol for a cluster randomised implementation trial to evaluate the effectiveness of de-implementation strategies to reduce low-value statin prescribing in the primary prevention of cardiovascular disease

    BMJ Open, Vol. 14, Núm. 4

  5. Elimination of hepatitis C virus in a prison: An 18-year experience

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 236-241

  6. Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus

    Expert Opinion on Pharmacotherapy

  7. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort

    Arthritis Care and Research, Vol. 76, Núm. 8, pp. 1132-1138

  8. Obstetric antiphospholipid syndrome

    Medicina Clinica, Vol. 163, pp. S14-S21

  9. Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

    Seminars in Arthritis and Rheumatism, Vol. 66

  10. Routine biomarker profile for the prediction of clinical phenotypes of adult-onset Still's disease using unsupervised clustering algorithm

    International Journal of Rheumatic Diseases, Vol. 27, Núm. 4

  11. Thrombotic antiphospholipid syndrome: From guidelines to clinical management

    Medicina Clinica, Vol. 163, pp. S22-S30

  12. Use of Glucocorticoids in SLE: A Clinical Approach

    Mediterranean Journal of Rheumatology, Vol. 35, pp. 342-353

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. ANCA-associated pulmonary-renal syndrome treated with cyclophosphamide, rituximab, repeated methyl-prednisolone pulses and a reduced oral glucocorticoid regime: an observational study

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 928-935

  3. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

    Arthritis Care and Research, Vol. 75, Núm. 9, pp. 1859-1870

  4. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort

    Arthritis and Rheumatology, Vol. 75, Núm. 12, pp. 2195-2206

  5. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  6. Factors associated with the hospital at home workload: A Delphi consensus study

    Journal of Healthcare Quality Research, Vol. 38, Núm. 4, pp. 233-244

  7. Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 984-995

  8. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

    The Lancet Rheumatology